HRP20230812T1 - Onkolitički virus i metoda - Google Patents
Onkolitički virus i metoda Download PDFInfo
- Publication number
- HRP20230812T1 HRP20230812T1 HRP20230812TT HRP20230812T HRP20230812T1 HR P20230812 T1 HRP20230812 T1 HR P20230812T1 HR P20230812T T HRP20230812T T HR P20230812TT HR P20230812 T HRP20230812 T HR P20230812T HR P20230812 T1 HRP20230812 T1 HR P20230812T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- combination
- virus
- agonist
- use according
- Prior art date
Links
- 244000309459 oncolytic virus Species 0.000 title claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 241000700605 Viruses Species 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims 3
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims 3
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 claims 2
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 229940121731 CD226 agonist Drugs 0.000 claims 1
- 229940121697 CD27 agonist Drugs 0.000 claims 1
- 229940123205 CD28 agonist Drugs 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940125563 LAG3 inhibitor Drugs 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 229940125555 TIGIT inhibitor Drugs 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 239000003183 carcinogenic agent Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (16)
1. Onkolitički virus koji sadrži transgensku kazetu koja kodira anti-CD40 protutijelo, pri čemu virus sadrži SEQ ID NO: 1.
2. Onkolitički virus sukladno zahtjevu 1, naznačen time što se sastoji od SEQ ID NO: 1.
3. Farmaceutski pripravak koji sadrži virus sukladno zahtjevu 1 ili 2, i farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili nosač.
4. Onkolitički virus sukladno zahtjevu 1 ili 2 ili farmaceutski pripravak sukladno zahtjevu 3, naznačen time, da se koristi u terapiji.
5. Onkolitički virus za uporabu sukladno zahtjevu 4, naznačen time što se virus primjenjuje u prvom tjednu na dane 1, 3 i 5 i u tjednu 2 na dane 1, 3 i 5.
6. Onkolitički virus sukladno zahtjevu 1 ili 2 ili farmaceutski pripravak sukladno zahtjevu 3, naznačen time, da se koristi u liječenju karcinoma, inzulinske rezistencije, pretilosti i/ili imunološkog nedostatka.
7. Onkolitički virus ili farmaceutski pripravak za uporabu sukladno zahtjevu 6, naznačen time što je virus ili pripravak za uporabu u liječenju karcinoma.
8. Onkolitički virus ili farmaceutski pripravak za uporabu sukladno zahtjevu 7, naznačen time što je virus ili pripravak za uporabu u liječenju karcinoma koji eksprimira CD40.
9. Kombinacija koja sadrži virus sukladno zahtjevima 1 ili 2 ili pripravak sukladno zahtjevu 3 i daljnje sredstvo protiv karcinoma za uporabu u liječenju karcinoma.
10. Kombinacija za uporabu sukladno zahtjevu 9, naznačena time što je daljnje sredstvo protiv karcinoma kemoterapijsko sredstvo.
11. Kombinacija za uporabu sukladno zahtjevu 9 ili 10, naznačena time što je daljnje sredstvo protiv karcinoma inhibitor kontrolne točke.
12. Kombinacija za uporabu sukladno zahtjevu 11, naznačena time što je sredstvo protiv karcinoma odabrano iz skupine koja sadrži PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, TIM-3 inhibitor, LAG-3 inhibitor, TIGIT inhibitor, B7-H3 (CD276) inhibitor, B7-H4 (B7S1) inhibitor, B7H7 (HHLA2) inhibitor, CD96 inhibitor, VISTA inhibitor i kombinacija dva ili više istih.
13. Kombinacija za uporabu sukladno zahtjevu 11 ili 12, naznačena time što je daljnje sredstvo protiv karcinoma agonist kostimulacijskog puta.
14. Kombinacija za uporabu sukladno zahtjevu 13, pri čemu je daljnje sredstvo protiv karcinoma odabrano iz skupine koja sadrži CD27 agonist, CD28 agonist, ICOS agonist, TMIGD2 (IGPR-1/CD28H) agonist, CD226 agonist, 0X40 agonist, 4-1BB agonist i kombinaciju dva ili više istih.
15. Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 9 do 14, naznačena time što daljnje sredstvo protiv karcinoma aktivira imunološke odgovore ili obrće supresiju imunoloških odgovora.
16. Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 9 do 15, naznačena time što je daljnji agens karcinoma onkolitički virus.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1708778.4A GB201708778D0 (en) | 2017-06-01 | 2017-06-01 | Virus and method |
| GBGB1708779.2A GB201708779D0 (en) | 2017-06-01 | 2017-06-01 | Virus and method |
| EP18732263.1A EP3630143B1 (en) | 2017-06-01 | 2018-06-01 | Oncolytic virus and method |
| PCT/EP2018/064524 WO2018220207A1 (en) | 2017-06-01 | 2018-06-01 | Oncolytic virus and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230812T1 true HRP20230812T1 (hr) | 2023-11-24 |
Family
ID=62683158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230812TT HRP20230812T1 (hr) | 2017-06-01 | 2018-06-01 | Onkolitički virus i metoda |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11142580B2 (hr) |
| EP (2) | EP3630143B1 (hr) |
| JP (1) | JP7394628B2 (hr) |
| KR (1) | KR20200026835A (hr) |
| CN (1) | CN111246867B (hr) |
| AU (1) | AU2018277294A1 (hr) |
| BR (1) | BR112019024918A2 (hr) |
| CA (1) | CA3063652A1 (hr) |
| CL (1) | CL2019003393A1 (hr) |
| CO (1) | CO2019013220A2 (hr) |
| DK (1) | DK3630143T3 (hr) |
| ES (1) | ES2952601T3 (hr) |
| FI (1) | FI3630143T3 (hr) |
| HR (1) | HRP20230812T1 (hr) |
| HU (1) | HUE063274T2 (hr) |
| IL (1) | IL270989B2 (hr) |
| LT (1) | LT3630143T (hr) |
| MX (1) | MX2019014184A (hr) |
| MY (1) | MY197684A (hr) |
| PH (1) | PH12019502522A1 (hr) |
| PL (1) | PL3630143T3 (hr) |
| PT (1) | PT3630143T (hr) |
| SI (1) | SI3630143T1 (hr) |
| WO (1) | WO2018220207A1 (hr) |
| ZA (1) | ZA201907351B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3288573T1 (sl) * | 2015-04-30 | 2020-06-30 | Psioxus Therapeutics Limited | Onkolitični adenovirus, ki kodira protein B7 |
| AU2021303412A1 (en) * | 2020-07-06 | 2023-02-09 | Salk Institute For Biological Studies | Recombinant adenovirus genome having a synthetic transcriptional unit and two step transcriptional regulation and amplification |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| CN113355296A (zh) * | 2021-06-07 | 2021-09-07 | 中国人民解放军空军军医大学 | 一种表达人ccl19的重组溶瘤新城疫病毒及其应用 |
| US11873507B2 (en) * | 2021-11-29 | 2024-01-16 | Replicate Bioscience, Inc. | Compositions and methods for expression of IL-12 and IL-1RA |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| ES2308989T3 (es) * | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
| GB0109002D0 (en) | 2001-04-10 | 2001-05-30 | Glaxo Group Ltd | Dispenser |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US7989594B2 (en) | 2003-07-01 | 2011-08-02 | Celltech R & D Limited | Modified antibody fab fragments |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| US7510868B2 (en) | 2004-05-26 | 2009-03-31 | Paul Harden | Chimeric adenoviruses for use in cancer treatment |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| JP5448840B2 (ja) | 2006-12-22 | 2014-03-19 | プシオクサス・セラピューティクス・リミテッド | 腫瘍退縮アデノウイルスの作出およびその使用 |
| ES2622460T3 (es) | 2007-09-26 | 2017-07-06 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| KR101526843B1 (ko) | 2007-11-29 | 2015-06-08 | 글락소 그룹 리미티드 | 분배 장치 |
| SI2334705T1 (sl) | 2008-09-26 | 2017-05-31 | Ucb Biopharma Sprl | Biološki produkti |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| KR20150122674A (ko) * | 2013-02-28 | 2015-11-02 | 싸이오서스 테라퓨틱스 엘티디. | 아데노바이러스의 생산 방법 |
| GB201322851D0 (en) * | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| GB201318793D0 (en) | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
| PL3021859T3 (pl) | 2013-10-25 | 2018-06-29 | Psioxus Therapeutics Limited | Adenowirusy onkolityczne wyposażone w geny heterolityczne |
| EP3180357B1 (en) * | 2014-08-14 | 2019-07-03 | F.Hoffmann-La Roche Ag | Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 |
| JP2017529070A (ja) * | 2014-08-27 | 2017-10-05 | サイオクサス セラピューティクス リミテッド | アデノウイルスの製造方法 |
| SI3288573T1 (sl) * | 2015-04-30 | 2020-06-30 | Psioxus Therapeutics Limited | Onkolitični adenovirus, ki kodira protein B7 |
| MX2018011306A (es) | 2016-03-18 | 2019-08-16 | Nantcell Inc | Vector multimodal para infeccion de celulas dentriticas. |
| CA3040296A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
-
2018
- 2018-06-01 MX MX2019014184A patent/MX2019014184A/es unknown
- 2018-06-01 BR BR112019024918-4A patent/BR112019024918A2/pt unknown
- 2018-06-01 KR KR1020197038939A patent/KR20200026835A/ko not_active Application Discontinuation
- 2018-06-01 CA CA3063652A patent/CA3063652A1/en active Pending
- 2018-06-01 PT PT187322631T patent/PT3630143T/pt unknown
- 2018-06-01 EP EP18732263.1A patent/EP3630143B1/en active Active
- 2018-06-01 HU HUE18732263A patent/HUE063274T2/hu unknown
- 2018-06-01 DK DK18732263.1T patent/DK3630143T3/da active
- 2018-06-01 AU AU2018277294A patent/AU2018277294A1/en active Pending
- 2018-06-01 WO PCT/EP2018/064524 patent/WO2018220207A1/en unknown
- 2018-06-01 MY MYPI2019006893A patent/MY197684A/en unknown
- 2018-06-01 IL IL270989A patent/IL270989B2/en unknown
- 2018-06-01 PL PL18732263.1T patent/PL3630143T3/pl unknown
- 2018-06-01 HR HRP20230812TT patent/HRP20230812T1/hr unknown
- 2018-06-01 ES ES18732263T patent/ES2952601T3/es active Active
- 2018-06-01 JP JP2019566331A patent/JP7394628B2/ja active Active
- 2018-06-01 LT LTEPPCT/EP2018/064524T patent/LT3630143T/lt unknown
- 2018-06-01 US US16/618,068 patent/US11142580B2/en active Active
- 2018-06-01 SI SI201830980T patent/SI3630143T1/sl unknown
- 2018-06-01 FI FIEP18732263.1T patent/FI3630143T3/fi active
- 2018-06-01 CN CN201880035279.3A patent/CN111246867B/zh active Active
- 2018-06-01 EP EP23170353.9A patent/EP4269438A3/en active Pending
-
2019
- 2019-11-05 ZA ZA2019/07351A patent/ZA201907351B/en unknown
- 2019-11-11 PH PH12019502522A patent/PH12019502522A1/en unknown
- 2019-11-21 CL CL2019003393A patent/CL2019003393A1/es unknown
- 2019-11-26 CO CONC2019/0013220A patent/CO2019013220A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI3630143T3 (fi) | 2023-08-22 |
| EP3630143A1 (en) | 2020-04-08 |
| IL270989A (en) | 2020-01-30 |
| BR112019024918A2 (pt) | 2020-06-23 |
| JP7394628B2 (ja) | 2023-12-08 |
| CO2019013220A2 (es) | 2020-05-15 |
| IL270989B1 (en) | 2023-10-01 |
| LT3630143T (lt) | 2023-09-25 |
| PT3630143T (pt) | 2023-08-29 |
| WO2018220207A1 (en) | 2018-12-06 |
| US20200140563A1 (en) | 2020-05-07 |
| MX2019014184A (es) | 2020-08-03 |
| PL3630143T3 (pl) | 2023-10-30 |
| EP4269438A2 (en) | 2023-11-01 |
| MY197684A (en) | 2023-07-04 |
| KR20200026835A (ko) | 2020-03-11 |
| US11142580B2 (en) | 2021-10-12 |
| CA3063652A1 (en) | 2018-12-06 |
| IL270989B2 (en) | 2024-02-01 |
| ES2952601T3 (es) | 2023-11-02 |
| EP4269438A3 (en) | 2024-01-24 |
| JP2020521496A (ja) | 2020-07-27 |
| ZA201907351B (en) | 2021-04-28 |
| AU2018277294A1 (en) | 2019-12-05 |
| HUE063274T2 (hu) | 2024-01-28 |
| CL2019003393A1 (es) | 2020-05-08 |
| DK3630143T3 (da) | 2023-08-14 |
| EP3630143B1 (en) | 2023-06-07 |
| CN111246867B (zh) | 2024-04-12 |
| CN111246867A (zh) | 2020-06-05 |
| PH12019502522A1 (en) | 2020-07-20 |
| SI3630143T1 (sl) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230812T1 (hr) | Onkolitički virus i metoda | |
| Vijayakumar et al. | Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines | |
| Collin | Immune checkpoint inhibitors: a patent review (2010-2015) | |
| Gravbrot et al. | Therapeutic monoclonal antibodies targeting immune checkpoints for the treatment of solid tumors | |
| Zhang et al. | Anti-West Nile virus activity of in vitro expanded human primary natural killer cells | |
| JP2017502690A5 (hr) | ||
| JP2016531907A5 (hr) | ||
| JP2019522657A5 (hr) | ||
| JP2019506428A5 (hr) | ||
| JP2018510143A5 (hr) | ||
| Lacayo et al. | Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma | |
| González-Rodríguez et al. | Lenalidomide and chronic lymphocytic leukemia | |
| Rajani et al. | Harnessing the power of onco-immunotherapy with checkpoint inhibitors | |
| CY1123839T1 (el) | Διειδικα αντισωματα για χρηση στην ανοσοθεραπεια του καρκινου | |
| MX2019005212A (es) | Vacuna de adn dirigida a wt1 para terapia de combinacion. | |
| JP2020522555A5 (hr) | ||
| Voorhees et al. | Management of infusion-related reactions following daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius) | |
| Grottoli et al. | Immune checkpoint blockade: A strategy to unleash the potential of natural killer cells in the anti-cancer therapy | |
| Efebera et al. | First interim results of a phase I/II study of lenalidomide in combination with anti-PD-1 monoclonal antibody MDV9300 (CT-011) in patients with relapsed/refractory multiple myeloma | |
| FI3452053T3 (fi) | Menetelmä alempien virtsateiden uroteelisyövän hoitamiseksi | |
| Matous et al. | MM-008: a phase 1 trial evaluating pharmacokinetics and tolerability of pomalidomide+ low-dose dexamethasone in patients with relapsed or refractory and refractory multiple myeloma and renal impairment | |
| JP2019527236A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| Xu et al. | CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection | |
| Hoffman et al. | SEA-BCMA, an investigational nonfucosylated monoclonal antibody: ongoing results of a phase 1 study in patients with relapsed/refractory multiple myeloma (SGNBCMA-001) | |
| HRP20240037T1 (hr) | Car t-stanice prema bcma za liječenje multiplog mijeloma |